These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 14695143)
1. Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma. Alsina J; Gorsk DH; Germino FJ; Shih W; Lu SE; Zhang ZG; Yang JM; Hait WN; Goydos JS Clin Cancer Res; 2003 Dec; 9(17):6419-25. PubMed ID: 14695143 [TBL] [Abstract][Full Text] [Related]
2. Detection of B-RAF and N-RAS mutations in human melanoma. Goydos JS; Mann B; Kim HJ; Gabriel EM; Alsina J; Germino FJ; Shih W; Gorski DH J Am Coll Surg; 2005 Mar; 200(3):362-70. PubMed ID: 15737846 [TBL] [Abstract][Full Text] [Related]
3. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Satyamoorthy K; Li G; Gerrero MR; Brose MS; Volpe P; Weber BL; Van Belle P; Elder DE; Herlyn M Cancer Res; 2003 Feb; 63(4):756-9. PubMed ID: 12591721 [TBL] [Abstract][Full Text] [Related]
4. Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Panka DJ; Atkins MB; Mier JW Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2371s-2375s. PubMed ID: 16609061 [TBL] [Abstract][Full Text] [Related]
5. Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-kappaB, but not c-Jun N-terminal kinase and activated protein-1. Gulati AP; Yang YM; Harter D; Mukhopadhyay A; Aggarwal BB; Benzil DL; Whysner J; Albino AP; Murali R; Jhanwar-Uniyal M Mol Carcinog; 2006 Jan; 45(1):26-37. PubMed ID: 16267831 [TBL] [Abstract][Full Text] [Related]
6. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma. Yang R; Piperdi S; Gorlick R Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278 [TBL] [Abstract][Full Text] [Related]
7. Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma. Ellerhorst JA; Ekmekcioglu S; Johnson MK; Cooke CP; Johnson MM; Grimm EA Oncogene; 2006 Jun; 25(28):3956-62. PubMed ID: 16474847 [TBL] [Abstract][Full Text] [Related]
8. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Zuidervaart W; van Nieuwpoort F; Stark M; Dijkman R; Packer L; Borgstein AM; Pavey S; van der Velden P; Out C; Jager MJ; Hayward NK; Gruis NA Br J Cancer; 2005 Jun; 92(11):2032-8. PubMed ID: 15928660 [TBL] [Abstract][Full Text] [Related]
9. Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations. Burger M; Denzinger S; Hammerschmied C; Tannapfel A; Maderstorfer A; Wieland WF; Hartmann A; Stoehr R Eur Urol; 2006 Nov; 50(5):1102-9; discussion 1109-10. PubMed ID: 16413100 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208 [TBL] [Abstract][Full Text] [Related]
11. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Bloethner S; Chen B; Hemminki K; Müller-Berghaus J; Ugurel S; Schadendorf D; Kumar R Carcinogenesis; 2005 Jul; 26(7):1224-32. PubMed ID: 15760917 [TBL] [Abstract][Full Text] [Related]
12. A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. Demunter A; Ahmadian MR; Libbrecht L; Stas M; Baens M; Scheffzek K; Degreef H; De Wolf-Peeters C; van Den Oord JJ Cancer Res; 2001 Jun; 61(12):4916-22. PubMed ID: 11406571 [TBL] [Abstract][Full Text] [Related]
13. Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays. Nambiar S; Mirmohammadsadegh A; Doroudi R; Gustrau A; Marini A; Roeder G; Ruzicka T; Hengge UR Arch Dermatol; 2005 Feb; 141(2):165-73. PubMed ID: 15724012 [TBL] [Abstract][Full Text] [Related]
14. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Liu ZJ; Xiao M; Balint K; Smalley KS; Brafford P; Qiu R; Pinnix CC; Li X; Herlyn M Cancer Res; 2006 Apr; 66(8):4182-90. PubMed ID: 16618740 [TBL] [Abstract][Full Text] [Related]
15. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Sharma A; Trivedi NR; Zimmerman MA; Tuveson DA; Smith CD; Robertson GP Cancer Res; 2005 Mar; 65(6):2412-21. PubMed ID: 15781657 [TBL] [Abstract][Full Text] [Related]
16. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Schuierer MM; Bataille F; Hagan S; Kolch W; Bosserhoff AK Cancer Res; 2004 Aug; 64(15):5186-92. PubMed ID: 15289323 [TBL] [Abstract][Full Text] [Related]
17. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Omholt K; Karsberg S; Platz A; Kanter L; Ringborg U; Hansson J Clin Cancer Res; 2002 Nov; 8(11):3468-74. PubMed ID: 12429636 [TBL] [Abstract][Full Text] [Related]
18. Raf: a strategic target for therapeutic development against cancer. Beeram M; Patnaik A; Rowinsky EK J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185 [TBL] [Abstract][Full Text] [Related]
19. Hyperactive Ras in developmental disorders and cancer. Schubbert S; Shannon K; Bollag G Nat Rev Cancer; 2007 Apr; 7(4):295-308. PubMed ID: 17384584 [TBL] [Abstract][Full Text] [Related]
20. Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic airways. Liu W; Liang Q; Balzar S; Wenzel S; Gorska M; Alam R J Allergy Clin Immunol; 2008 Apr; 121(4):893-902.e2. PubMed ID: 18395552 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]